

CITATION REPORT

List of articles citing

Chloroquine neuromyotoxicity. Clinical and pathologic persp

DOI: 10.1016/0002-9343(87)90444-x
American Journal of Medicine, 1987, 82, 447-55.

Source: <https://exaly.com/paper-pdf/19125640/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
173	Cerebellar ataxia in patients with malaria treated with chloroquine. 1988 , 64, 167		12
172	Survival after chloroquine ingestion in a child. 1988 , 26, 381-8		5
171	Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 38-1988. A 58-year-old woman with fever, sweats, congestive heart failure, and lymphadenopathy after treatment for a diagnosis of systemic lupus erythematosus. 1988 , 319, 768-81		17
170	Toxic Myopathies. <i>Neurologic Clinics</i> , 1988 , 6, 593-619	4.5	20
169	Clinical features, pathogenesis and management of drug-induced rhabdomyolysis. 1989 , 4, 108-26		67
168	A review of the biology and toxicologic implications of the induction of lysosomal lamellar bodies by drugs. 1989 , 97, 47-56		104
167	Antimalarials. 1989 , 7, 60-8		2
166	Antiprotozoal drugs. 1989 , 13, 238-245		
165	Drug-induced myopathies. 1990 , 19, 259-68		13
164	AAEM minimonograph #34: polyneuropathy: classification by nerve conduction studies and electromyography. <i>Muscle and Nerve</i> , 1990 , 13, 889-903	3.4	131
163	Antiprotozoal drugs. 1991 , 15, 286-307		1
162	Quality monitor implementation for standards of care of the mechanically ventilated patient. 1991 , 2, 77-81		
161	Drug-induced myopathies. 1991 , 5, 21-38		51
160	Rheumatic syndromes caused by antirheumatic drugs. 1991 , 5, 139-73		5
159	AAEM case report #22: polymyositis. <i>Muscle and Nerve</i> , 1991 , 14, 310-5	3.4	21
158	Neuropathies and myopathies complicating HIV infection. 1991 , 6, 110-21		1
157	Neurotoxic effects of chloroquine in vitro. 1991 , 65, 480-4		28

156	Prevention and management of drug-induced peripheral neuropathy. <i>Drug Safety</i> , 1991 , 6, 302-14	5.1	9
155	Not Myositis. 1992 , 268, 2074		6
154	[Iatrogenic neuropathies]. 1992 , 13, 225-32		5
153	Lysosomal glycosphingolipid storage in chloroquine-induced alpha-galactosidase-deficient human endothelial cells with transformation by simian virus 40: in vitro model of Fabry disease. 1993 , 85, 272-9		11
152	[Cardiomyopathy under treatment with hydroxychloroquine disclosed by complete auriculoventricular block]. 1993 , 14, 275-6		8
151	Restrictive cardiomyopathy caused by chloroquine. 1993 , 69, 451-2		54
150	Histological and ultrastructural findings in chloroquine-induced cardiomyopathy. 1995 , 73, 73-7		28
149	Respiratory failure associated with hydroxychloroquine neuromyopathy. 1995 , 35, 236-7		7
148	Acquired Brown@ syndrome and primary Sjogren@ syndrome. 1995 , 79, 89-90		12
147	Incidence of myopathy in patients treated with antimalarials. A report of three cases and a review of the literature. 1995 , 34, 166-70		39
146	Syndrome cBelleux et paludisme. 1995 , 25, 1115-1118		
145	Eye damage from chloroquine as an antimalarial: misuse makes safe medicines unsafe. 1997 , 27, 10-2		
144	Familial interstitial lung disease in children: response to chloroquine treatment in one sibling with desquamative interstitial pneumonitis. 1997 , 23, 55-61		21
143	Reactions and interactions of some commonly used systemic drugs in dermatology. 1998 , 16, 421-9		14
142	Pulmonary toxicity of drugs used to treat systemic autoimmune diseases. 1998 , 19, 809-21, x		20
141	Chloroquine myopathy and neuropathy with elevated CSF protein. <i>Neurology</i> , 1998 , 51, 1226-7	6.5	21
140	Chloroquine cardiomyopathy with conduction disorders. 1999 , 81, 221-3		45
139	Propofol-associated Rhabdomyolysis with Cardiac Involvement in Adults: Chemical and Anatomic Findings. 2000 , 46, 577-581		92

138	Hydroxychloroquine for the treatment of chronic graft-versus-host disease. 2000 , 6, 327-34		94
137	Metabolic myopathies. A diagnostic evaluation. <i>Neurologic Clinics</i> , 2000 , 18, 1-13	4.5	15
136	Old and new drugs used in rheumatoid arthritis: a historical perspective. Part 1: the older drugs. 2001 , 8, 123-43		36
135	Morphological studies on CLN2. 2001 , 5 Suppl A, 203-7		5
134	Neurologische Komplikationen der Therapie rheumatischer Erkrankungen. <i>Aktuelle Rheumatologie</i> , 2001 , 26, 285-290	0.1	
133	Ciprofloxacin-related acute peripheral neuropathy in a patient with lupus nephritis. 2002 , 8, 143-6		2
132	Chloroquine cardiotoxicity: clinicopathologic features in three patients and comparison with three patients with Fabry disease. 2002 , 11, 277-83		58
131	Cardiac damage from chronic use of chloroquine: a case report and review of the literature. 2002 , 79, 85-8		27
130	Differential diagnosis of high serum creatine kinase levels in systemic lupus erythematosus. <i>Rheumatology International</i> , 2003 , 23, 319-23	3.6	8
129	Drug-induced and toxic myopathies. 2003 , 17, 877-907		44
128	Iatrogenic and toxic myopathies. <i>Muscle and Nerve</i> , 2003 , 27, 142-56	3.4	67
127	Increased CSF protein in chloroquine-induced axonal polyneuropathy and myopathy. 2003 , 105, 231-6		7
126	Chapter 32 Toxic myopathies. 2003 , 2, 621-650		
125	Cardiomyopathies spécifiques au cours du lupus érythémateux systémique : à propos de 3 cas. 2004 , 71, 78-81		
124	Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of the literature. 2004 , 33, 336-51		94
123	Specific cardiomyopathy in lupus patients: report of three cases. 2004 , 71, 66-9		15
122	An unusual cause of dyspnea. 2004 , 12, 10-4		
121	[Occurrence of chloroquine-induced myopathy after low-dose treatment of rheumatoid arthritis for seven years]. 2005 , 64, 274-6		1

120	Hydroxychloroquine causes severe vacuolar myopathy in a patient with chronic graft-versus-host disease. 2005 , 78, 306-9		36
119	Ocular toxicity due to chloroquine and hydroxychloroquine: electrophysiological and visual function correlates. 2005 , 110, 111-20		48
118	Chloroquine-induced cardiomyopathy-echocardiographic features. 2005 , 18, 383-7		31
117	Toxic myopathies. <i>Neurologic Clinics</i> , 2005 , 23, 397-428	4.5	56
116	Antimalarial myopathy: an underdiagnosed complication? Prospective longitudinal study of 119 patients. 2006 , 65, 385-90		93
115	Tolerability of amodiaquine and sulphadoxine-pyrimethamine, alone or in combination for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan adults. 2006 , 11, 589-96		15
114	Toxic and iatrogenic myopathies. 2007 , 86, 321-41		5
113	Hydroxychloroquine-induced restrictive cardiomyopathy. 2007 , 8, 247-51		35
112	Cardiomyopathy related to antimalarial therapy with illustrative case report. 2007 , 107, 73-80		76
111	Hydroxychloroquine-induced toxic myopathy causing respiratory failure. 2007 , 131, 588-90		49
110	Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases. 2007 , 46, 808-10		90
109	Severe, reversible dysphagia from chloroquine and hydroxychloroquine myopathy. 2007 , 34, 377-9		7
108	New clinical and ultrastructural findings in hydroxychloroquine-induced cardiomyopathy--a report of 2 cases. 2007 , 38, 1858-63		49
107	Anaesthesia and rheumatoid arthritis. 1993 , 48, 989-97		26
106	Severe hydroxychloroquine myopathy. <i>Muscle and Nerve</i> , 2008 , 38, 1206-10	3.4	56
105	[Retinal damage by (hydroxy)chloroquine intake: published evidence for an efficient ophthalmological follow-up]. 2009 , 226, 891-6		3
104	Cardiotoxicity after low-dose chloroquine antimalarial therapy. 2009 , 24, 385-7		14
103	Skeletal Muscle Toxicology. 2009 ,		

102	Endolysosomal phospholipidosis and cytosolic lipid droplet storage and release in macrophages. 2009 , 1791, 524-39			39
101	Cardiac pathology of systemic lupus erythematosus. 2009 , 62, 584-92			65
100	[Chloroquine cardiotoxicity in long-term lupus therapy in two patients]. 2009 , 136, 530-5			12
99	Fatigue au cours des maladies rhumatologiques. 2010 , 77, 563-567			
98	A case of chloroquine-induced cardiomyopathy that presented as sick sinus syndrome. 2010 , 40, 604-8			19
97	Toxicity and monitoring of immunosuppressive therapy used in systemic autoimmune diseases. 2010 , 31, 565-88			24
96	[Drug induced myopathies]. 2010 , 6 Suppl 2, 25-7			2
95	Drugs causing muscle disease. <i>Rheumatic Disease Clinics of North America</i> , 2011 , 37, 219-31, vi	2.4		17
94	Case records of the Massachusetts General Hospital. Case 11-2011. A 47-year-old man with systemic lupus erythematosus and heart failure. 2011 , 364, 1450-60			34
93	Essential muscle pathology for the rheumatologist. <i>Rheumatic Disease Clinics of North America</i> , 2011 , 37, 289-308, vii	2.4		2
92	Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease. 2011 , 17, 1-17			260
91	Antimalarials and SLE. 2011 , 1061-1081			0
90	Fatigue in patients with rheumatic diseases. 2011 , 78, 156-60			23
89	Chloroquine-induced myopathy. <i>Lupus</i> , 2011 , 20, 773-4	2.6		8
88	Heart. 2011 , 815-832			
87	Hydroxychloroquine-induced oxidative stress on sciatic nerve and muscle tissue of rats: a stereological and biochemical study. 2012 , 31, 1066-73			7
86	Safe use of antirheumatic agents in patients with comorbidities. <i>Rheumatic Disease Clinics of North America</i> , 2012 , 38, 771-93	2.4		4
85	Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects. 2012 , 42, 968-78			73

84	Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines. 2012 , 142, e1S-e111S		37
83	Clinical utility of LC3 and p62 immunohistochemistry in diagnosis of drug-induced autophagic vacuolar myopathies: a case-control study. 2012 , 7, e36221		57
82	Hydroxychloroquine: from malaria to autoimmunity. 2012 , 42, 145-53		348
81	Ultrasonographic evaluation of the muscle architecture in patients with systemic lupus erythematosus. <i>Clinical Rheumatology</i> , 2013 , 32, 1155-60	3.9	15
80	Chloroquine cardiomyopathy - a review of the literature. 2013 , 35, 434-42		120
79	Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: key diagnostic features and literature review. 2013 , 2, 77-83		92
78	Chloroquine causes similar electroretinogram modifications, neuronal phospholipidosis and marked impairment of synaptic vesicle transport in albino and pigmented rats. 2013 , 308, 50-9		10
77	LC3 and p62 as diagnostic markers of drug-induced autophagic vacuolar cardiomyopathy: a study of 3 cases. 2013 , 37, 1014-21		18
76	Myopathy, Toxic. 2014 , 282-285		
75	Hydroxychloroquine-induced cardiomyopathy: case report, pathophysiology, diagnosis, and treatment. 2014 , 30, 1706-15		92
74	Toxic Myopathies. 2014 , 1403-1426		
73	Toxic neuropathies. 2014 , 238-246		1
72	Hydroxychloroquine and Chloroquine Retinopathy. 2014 ,		25
71	Pharmacology of Chloroquine and Hydroxychloroquine. 2014 , 35-63		65
70	Toxic myopathies. <i>Neurologic Clinics</i> , 2014 , 32, 647-70, viii	4.5	31
69	Toxic Neuropathies. <i>Seminars in Neurology</i> , 2015 , 35, 448-57	3.2	16
68	A Case of Neuromyopathy Due to Synthetic Antimalarial Drugs. <i>Epidemiology (Sunnyvale, Calif)</i> , 2016 , 06,	0	
67	Activation of the Keap1/Nrf2 stress response pathway in autophagic vacuolar myopathies. <i>Acta Neuropathologica Communications</i> , 2016 , 4, 115	7.3	15

66	Neurologische Komplikationen antirheumatischer Pharmakotherapeutika. <i>Aktuelle Rheumatologie</i> , 2016 , 41, 243-252	0.1	
65	The pathological diagnosis of nerve biopsies: a practical approach. <i>Diagnostic Histopathology</i> , 2016 , 22, 333-344	0.7	4
64	An explanatory model of functional exercise capacity in patients with systemic sclerosis: considerations for rehabilitation programs. <i>Journal of Physical Therapy Science</i> , 2016 , 28, 569-75	1	3
63	Myopathies induites par les médicaments. <i>Toxicologie Analytique Et Clinique</i> , 2017 , 29, 186-204	0.4	
62	Antimalarial myopathy in a systemic lupus erythematosus patient with quadriplegia and seizures: a case-based review. <i>Clinical Rheumatology</i> , 2017 , 36, 1437-1444	3.9	5
61	Protocolo diagnóstico diferencial de las miopatías en la artritis reumatoide. <i>Medicine</i> , 2017 , 12, 1672-1676	0.1	
60	Restrictive Cardiomyopathy Associated With Long-Term Use of Hydroxychloroquine for Systemic Lupus Erythematosus. <i>Journal of Pharmacy Practice</i> , 2017 , 30, 571-575	1.3	4
59	Curvilinear bodies are associated with adverse effects on muscle function but not with hydroxychloroquine dosing. <i>Clinical Rheumatology</i> , 2017 , 36, 689-693	3.9	5
58	Chloroquine-induced cardiomyopathy: a reversible cause of heart failure. <i>ESC Heart Failure</i> , 2018 , 5, 372-375	3.7	26
57	Antimalarial-induced cardiomyopathy: a systematic review of the literature. <i>Lupus</i> , 2018 , 27, 591-599	2.6	32
56	Hydroxychloroquine-induced autophagic vacuolar myopathy with mitochondrial abnormalities. <i>Neuropathology</i> , 2018 , 38, 646-652	2	20
55	Histopathology of the muscle in rheumatic diseases. <i>Reumatismo</i> , 2018 , 70, 133-145	1.1	1
54	Detecting Toxic Myopathies as Medication Side Effect. <i>Physical Medicine and Rehabilitation Clinics of North America</i> , 2018 , 29, 659-667	2.3	
53	Toxic myopathies. <i>Current Opinion in Neurology</i> , 2018 , 31, 575-582	7.1	15
52	Spontaneous hypertrophic cardiomyopathy in a cynomolgus macaque (). <i>Journal of Toxicologic Pathology</i> , 2018 , 31, 49-54	1.4	4
51	Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature. <i>Drug Safety</i> , 2018 , 41, 919-931	5.1	195
50	Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review. <i>Clinical Drug Investigation</i> , 2018 , 38, 653-671	3.2	152
49	Neuropathy of Connective Tissue Diseases and Other Systemic Diseases. <i>Seminars in Neurology</i> , 2019 , 39, 651-668	3.2	4

48	Pearls & Oysters: Hydroxychloroquine-induced toxic myopathy mimics Pompe disease: Critical role of genetic test. <i>Neurology</i> , 2019 , 92, e742-e745	6.5	12
47	Muscle Toxicity of Drugs: When Drugs Turn Physiology into Pathophysiology. <i>Physiological Reviews</i> , 2020 , 100, 633-672	47.9	14
46	Chloroquine to fight COVID-19: A consideration of mechanisms and adverse effects?. <i>Heliyon</i> , 2020 , 6, e04900	3.6	9
45	Side Effects of Chloroquine and Hydroxychloroquine on Skeletal Muscle: a Narrative Review. <i>Current Pharmacology Reports</i> , 2020 , 6, 1-9	5.5	10
44	S1-Leitlinie: Diagnostik und Differenzialdiagnose bei Myalgien. <i>DGNeurologie</i> , 2020 , 3, 206-222	0.2	1
43	Janus sword actions of chloroquine and hydroxychloroquine against COVID-19. <i>Cellular Signalling</i> , 2020 , 73, 109706	4.9	13
42	Reductive stress in striated muscle cells. <i>Cellular and Molecular Life Sciences</i> , 2020 , 77, 3547-3565	10.3	19
41	Dermatomyositis: An Update on Diagnosis and Treatment. <i>American Journal of Clinical Dermatology</i> , 2020 , 21, 339-353	7.1	21
40	COVID-19 and neuromuscular disorders. <i>Neurology</i> , 2020 , 94, 959-969	6.5	157
39	Chloroquine- and Hydroxychloroquine-Induced Cardiomyopathy: A Case Report and Brief Literature Review. <i>American Journal of Clinical Pathology</i> , 2021 , 155, 793-801	1.9	2
38	Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose. <i>Clinical Toxicology</i> , 2021 , 59, 12-23	2.9	24
37	Drug-Induced Peripheral Neuropathies. 2021 , 437-467		
36	Overcoming Chemoresistance: Altering pH of Cellular Compartments by Chloroquine and Hydroxychloroquine. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 627639	5.7	10
35	Nerve biopsy: Current indications and decision tools. <i>Muscle and Nerve</i> , 2021 , 64, 125-139	3.4	8
34	Chloroquine and Hydroxychloroquine Myopathy: Clinical Spectrum and Treatment Outcomes. <i>Frontiers in Neurology</i> , 2020 , 11, 616075	4.1	5
33	Repurposing Chloroquine Against Multiple Diseases With Special Attention to SARS-CoV-2 and Associated Toxicity. <i>Frontiers in Pharmacology</i> , 2021 , 12, 576093	5.6	10
32	Systemic toxicity of chloroquine and hydroxychloroquine: prevalence, mechanisms, risk factors, prognostic and screening possibilities. <i>Rheumatology International</i> , 2021 , 41, 1189-1202	3.6	5
31	Na/K-ATPase as a Target of Cardiac Glycosides for the Treatment of SARS-CoV-2 Infection. <i>Frontiers in Pharmacology</i> , 2021 , 12, 624704	5.6	7

30	Autophagy Inhibitors Do Not Restore Peroxisomal Functions in Cells With the Most Common Peroxisome Biogenesis Defect. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 661298	5.7	6
29	Repurposed drug against COVID-19: nanomedicine as an approach for finding new hope in old medicines. <i>Nano Express</i> , 2021 , 2, 022007	2	2
28	The controversial therapeutic journey of chloroquine and hydroxychloroquine in the battle against SARS-CoV-2: A comprehensive review. <i>Medicine in Drug Discovery</i> , 2021 , 10, 100085	7	5
27	Artemisinin-Based Combination Therapy Synergized with Medicinal Plants to Induce Musculotoxic Effects. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021 , 2021, 8861574	2.3	1
26	Association between Leflunomide and Pulmonary Hypertension. <i>Annals of the American Thoracic Society</i> , 2021 , 18, 1306-1315	4.7	0
25	Pharmacokinetic and Pharmacodynamic Assessment of Hydroxychloroquine in Breast Cancer. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021 , 379, 331-342	4.7	0
24	On the importance of physicochemical parameters of copper and aminosilane functionalized mesoporous silica for hydroxychloroquine release. <i>Materials Science and Engineering C</i> , 2021 , 130, 112438	8.3	2
23	Periphere Neuropathie. 2006 , 303-328		0
22	Myopathie. 2006 , 343-357		0
21	Cardiomyopathy. 1991 , 239-255		2
20	Juvenile Rheumatoid Arthritis. 1993 , 231-359		6
19	Toxicology of Hydroxychloroquine and Chloroquine and the Pathology of the Retinopathy They Cause. 2014 , 65-83		3
18	Neuropathy Caused by Drugs. 2005 , 2553-2583		5
17	Acquired Neuropathies. 2002 , 937-1041		8
16	Toxic Myopathies. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2019 , 25, 1712-1731	3	14
15	Novel role of miR-29a in pancreatic cancer autophagy and its therapeutic potential. <i>Oncotarget</i> , 2016 , 7, 71635-71650	3.3	45
14	Hydroxychloroquine in COVID-19 Patients: Pros and Cons. <i>Frontiers in Pharmacology</i> , 2020 , 11, 597985	5.6	13
13	Spectrum of Neurological Manifestations in Covid-19: A Review. <i>Neurology India</i> , 2020 , 68, 560-572	0.7	54

12	Acquired Myopathies. 2002 , 1371-1432			1
11	Myopathy, Toxic. 2003 , 362-366			
10	Disorders of Skeletal Muscle. 2008 , 2403-2451			
9	Toxic Myopathies. 2009 , 159-173			
8	Drug-Induced Toxic Neuropathies. 2014 , 715-731			
7	DRUG-RELATED MYOPATHIES. <i>Rheumatic Disease Clinics of North America</i> , 1994 , 20, 1017-1032	2.4		14
6	Myositis Mimics: The Differential Diagnosis of Myositis. 2020 , 209-223			1
5	The management of patients with neurological diseases during the COVID-19 pandemic. <i>Arterial Hypertension (Russian Federation)</i> , 2020 , 26, 447-461	0.7		1
4	Drug repurposing in cancer neuroscience: From the viewpoint of the autophagy-mediated innervated niche. 13,			0
3	Biologic Functions of Hydroxychloroquine in Disease: From COVID-19 to Cancer. 2022 , 14, 2551			0
2	Toxic neuropathies: a practical approach. practneurol-2022-003444			0
1	Identifying and Managing Nociceptive Pain in Individuals With Rheumatic Diseases: A Narrative Review.			0